Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka city, Japan.
Molecular Oncology and Therapeutics, Osaka City University Graduate School of Medicine, Osaka city, Japan.
PLoS One. 2019 Nov 8;14(11):e0224727. doi: 10.1371/journal.pone.0224727. eCollection 2019.
Thrombospondin-4 [1] is an extracellular glycoprotein involved in wound healing and tissue remodeling. Although THBS4 is reportedly frequently expressed in solid tumors, there are few reports of the clinicopathological features of carcinomas with THBS4 expression. We evaluated the clinicopathologic significance of THBS4 expression in gastric carcinoma (GC).
We retrospectively analyzed the cases of 584 GC patients. The expression of THBS4 in each tumor was evaluated by immunohistochemistry. We then divided the patients into the THBS4-high (n = 223, 38.2%) group and THBS4-low (n = 361, 61.8%) group. THBS4 expression in cancer-associated fibroblasts (CAFs), normal-associated fibroblasts (NFs) and gastric cancer cell lines was examined by western blotting.
THBS4 is expressed on stromal cells with αSMA or Podoplanin expression in the GC microenvironment, but not expressed on cancer cells with cytokeratin expression. The western blot analysis results showed that CAFs (but not NFs and cancer cells) expressed THBS4. Compared to the THBS4-low expression status, the THBS4-high expression status was correlated with higher αSMA expression, higher invasion depth, lymph-node metastasis, lymphatic invasion, peritoneal cytology, peritoneal metastasis, larger tumor size, microscopic diffuse type, and the macroscopic diffuse infiltrating type. The THBS4-high group's 5-year overall survival rate was significantly poorer than that of the THBS4-low group. A multivariate analysis revealed that THBS4 expression was an independent prognostic factor.
THBS4 is expressed on CAFs in the gastric cancer microenvironment. THBS4 from CAFs is associated with the metastasis of cancer cells, and is a useful prognostic indicator for gastric cancer patients.
血小板反应蛋白 4[1]是一种参与伤口愈合和组织重塑的细胞外糖蛋白。尽管 THBS4 据报道在实体瘤中频繁表达,但关于表达 THBS4 的癌的临床病理特征的报道很少。我们评估了 THBS4 表达在胃癌(GC)中的临床病理意义。
我们回顾性分析了 584 例 GC 患者的病例。通过免疫组织化学评估每个肿瘤中 THBS4 的表达。然后,我们将患者分为 THBS4 高(n = 223,38.2%)组和 THBS4 低(n = 361,61.8%)组。通过 Western blot 检测癌症相关成纤维细胞(CAFs)、正常相关成纤维细胞(NFs)和胃癌细胞系中 THBS4 的表达。
THBS4 在 GC 微环境中表达于具有αSMA 或 Podoplanin 表达的基质细胞上,但不表达于具有细胞角蛋白表达的癌细胞上。Western blot 分析结果表明,CAFs(而非 NFs 和癌细胞)表达 THBS4。与 THBS4 低表达状态相比,THBS4 高表达状态与更高的αSMA 表达、更深的浸润深度、淋巴结转移、淋巴血管浸润、腹膜细胞学、腹膜转移、更大的肿瘤大小、显微镜下弥漫型和大体弥漫浸润型相关。THBS4 高组的 5 年总生存率明显低于 THBS4 低组。多因素分析显示,THBS4 表达是独立的预后因素。
THBS4 在胃癌微环境中的 CAFs 上表达。CAFs 来源的 THBS4 与癌细胞的转移有关,是胃癌患者有用的预后指标。